Diazepam

Introduction Overview

Generic Name

diazepam

Brand Name

Diastat AcuDial

Dosage Form

rectal gel

Drug Class

Benzodiazepine anticonvulsants

Pharmacokinetics

Absorption:
Diazepam demonstrated rapid and efficient absorption following rectal administration as a rectal gel, such as in Diastat AcuDial. The polymeric gel allows for depot formation in the rectal mucosa providing relatively rapid onset of diazepam plasma concentrations, with peak plasma levels typically achieved within 1 to 2 hours post-administration. Rectal absorption bypasses first-pass hepatic metabolism to some extent, yielding bioavailability estimates approximating that of oral formulations, which is usually around 90%. Absorption rates may be influenced by rectal blood flow, presence of fecal matter, and mucosal integrity, making correct administration technique essential for consistent pharmacokinetics.

Distribution:
Diazepam is highly lipophilic and extensively distributes into body tissues, including the central nervous system, consistent with its benzodiazepine class properties. It binds extensively to plasma proteins (~98-99%, primarily albumin), which influences its plasma half-life and tissue distribution. Distribution volume is large (0.8 to 1.0 L/kg), indicating extensive tissue uptake. Diazepam crosses the blood-brain barrier readily, resulting in rapid central nervous system effects, which is critical in controlling seizures. It also crosses the placenta and is excreted in breast milk, necessitating caution in pregnancy and lactation.

Metabolism:
Diazepam undergoes extensive hepatic metabolism mainly via cytochrome P450 isoenzymes CYP2C19 and CYP3A4. Metabolic pathways include N-demethylation to nordiazepam (desmethyldiazepam), hydroxylation to temazepam, and further oxidation. Nordiazepam is an active metabolite with similar pharmacological activity and a longer half-life, contributing to diazepam’s prolonged CNS effects. Factors such as hepatic impairment, age, and concomitant medications influencing CYP enzymes can significantly impact metabolism, necessitating dosage adjustments.

Elimination:
The elimination half-life of diazepam varies widely, generally ranging from 20 to 50 hours, influenced by its active metabolites which may have half-lives up to 100 hours. Diazepam and its metabolites are primarily eliminated via renal excretion after hepatic conjugation to glucuronides. Biliary excretion and enterohepatic recirculation can contribute to prolonging its systemic presence. In patients with hepatic or renal impairment, elimination may be significantly delayed, raising the risk for accumulation and toxicity. Clinical monitoring is advised in such populations.

Overall, the pharmacokinetics of diazepam rectal gel provides a practical and effective route of administration for acute seizure exacerbations, balancing rapid onset and sustained seizure control with a well-understood metabolic and elimination profile.

Dosage Forms

Available Dosage Forms:
Diastat AcuDial is available as a pre-filled rectal gel syringe coupled with a plastic applicator featuring a flexible molded tip. The gel formulation contains diazepam at concentrations correlating to the following syringe strengths and tip sizes:
- Diastat AcuDial 2.5 mg/0.5 mL (older Diastat formulation remains in limited availability)
- Diastat AcuDial 5 mg/2 mL
- Diastat AcuDial 10 mg/2 mL with a 4.4 cm tip
- Diastat AcuDial 20 mg/2 mL with a 6.0 cm tip
Each syringe has a dose window and a green band indicating dose readiness, facilitating accurate dosing.

Dosages for Adults and Adolescents:
Dosing is weight- and age-dependent, tailored for seizure cluster control:
- Ages 2-5 years: 0.5 mg/kg
- Ages 6-11 years: 0.3 mg/kg
- Ages 12 years and older: 0.2 mg/kg

Dosing tables provide precise weight ranges matched to specific dose strengths (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg) for use by healthcare providers and caregivers. Dose rounding may be necessary based on available syringe strengths.

Specific Patient Populations:
- Pediatric patients aged 2 years and older have established dosing guidelines, but safety and efficacy are not established for children under 2 years.
- Use in elderly or patients with hepatic or renal impairment requires caution due to altered pharmacokinetics and increased sensitivity.
- Administration technique and positioning during use are critical to ensure optimal absorption and minimize leakage.
- The device design enables caregivers to effectively administer the medication during seizure episodes safely.

Clinical Guidelines emphasize adherence to prescribed dosing and careful monitoring post-administration, including possible second dosing 4 to 12 hours after the initial dose if seizure activity persists as directed by the healthcare provider.

Mechanism Of Action

Diazepam, the active ingredient in Diastat AcuDial, exerts its therapeutic effect primarily by modulating gamma-aminobutyric acid (GABA) neurotransmission, which is the principal inhibitory neurotransmitter in the central nervous system. Diazepam binds to specific benzodiazepine binding sites on the GABA-A receptor complex, distinct from the GABA binding site. This allosteric binding enhances the affinity of GABA for its receptor, leading to increased frequency of chloride channel opening events.

This influx of chloride ions into neurons causes hyperpolarization of the neuronal membrane, reducing neuronal excitability and preventing the propagation of seizure activity. Neurons stabilized by diazepam are less likely to depolarize spontaneously, curtailing excessive synaptic firing that characterizes seizures.

Comparatively, diazepam is a potent benzodiazepine with rapid onset and relatively long half-life due to active metabolites such as nordiazepam. This contrasts with shorter-acting benzodiazepines used in acute settings. Its prolonged action facilitates sustained seizure control after administration. Additionally, diazepam’s lipophilicity aids in quick penetration across the blood-brain barrier, enhancing its effectiveness in terminating seizure clusters promptly.

Clinical studies underscore diazepam rectal gel’s efficacy in aborting clusters of seizures distinct from typical seizure patterns in epilepsy. The rectal route offers a practical alternative when intravenous access is not feasible, allowing caregivers to administer the drug rapidly. Emerging research continues to explore optimized delivery methods to balance rapid seizure termination with minimized sedation and respiratory depression risks.

Pharmacological Actions

Potentiates GABAergic neurotransmission by binding allosterically to GABA-A receptors
Enhances chloride ion influx into neurons, causing membrane hyperpolarization
Suppresses neuronal excitability and propagation of epileptiform activity
Exerts anticonvulsant properties effective in aborting acute seizure clusters
Provides anxiolytic effects due to CNS depressant activity
Induces muscle relaxation through inhibition of polysynaptic reflexes in spinal cord
Produces sedative and hypnotic actions via CNS depression
Exhibits amnestic effects at higher dosages affecting memory processes
Displays anticonvulsant activity with dose-dependent duration influenced by active metabolites
Acts as a central nervous system depressant with respiratory and cardiovascular effects at higher doses
Engages in interaction with other CNS depressants increasing sedation risk
Demonstrates high lipid solubility contributing to rapid CNS uptake
Modulates psychomotor and cognitive function secondary to GABA modulation
Displays ability to delay seizure propagation rather than preventing initiation
Contributes to overall neuroprotection by stabilizing overactive neuronal circuits during seizures

Therapeutic Or Clinical Uses

Management of acute repetitive seizures (seizure clusters) in epilepsy patients aged 2 years and older
Adjunct therapy for epilepsy requiring rapid seizure control outside hospital settings
Treatment of status epilepticus when intravenous access is unavailable or delayed
Short-term management of severe seizure exacerbations in patients with established epilepsy diagnosis
Reduction of seizure frequency during breakthrough episodes amidst chronic antiepileptic therapy
Emergency intervention in seizure emergencies in outpatient and home-care environments
Use in pediatric epilepsy seizure cluster management from 2 years upwards as approved
Off-label use in other acute seizure disorders where benzodiazepine therapy is indicated
Alternative benzodiazepine delivery in patients unable to tolerate oral or intravenous administration
Provision of rapid central nervous system depressant actions to interrupt epileptogenic neuronal circuits
Reduction in morbidity associated with prolonged or multiple seizure episodes
Facilitation of caregiver-administered rescue therapy to improve quality of life for epilepsy patients
Potential use in combination with other antiepileptic drugs to optimize seizure control
Temporary seizure control facilitating evaluation and initiation of longer-term therapies
Use in monitored settings to prevent seizure-related complications such as injury or hypoxia

Side Or Adverse Effects

Somnolence (most frequently reported side effect) including drowsiness and prolonged sedation
Dizziness and headache associated with central nervous system depression
Ataxia or incoordination presenting as impaired motor skills or balance difficulties
Nervousness or anxiety as paradoxical reactions in some patients
Gastrointestinal disturbances including abdominal pain and diarrhea
Respiratory depression, particularly when combined with other CNS depressants or opioids
Euphoria or mood changes leading to potential abuse or misuse
Rash and other hypersensitivity reactions including rare severe allergic responses
Muscle weakness, tremors, twitching, or abnormal sensations such as burning or prickling
Withdrawal symptoms upon abrupt discontinuation, including anxiety, insomnia, depression, and cognitive disturbances
Potential respiratory complications such as asthma exacerbation and rhinitis
Risk of addiction, tolerance, and physical dependence with prolonged or excessive use
Possible changes in behavior including agitation, paranoia, or delirium in susceptible patients
In rare cases, severe sedation leading to hypoventilation or apnea necessitating medical intervention
Transient memory impairment and cognitive dulling with repeated or high-dose administration

Precautions

Administer with caution in patients with respiratory disorders such as asthma or pneumonia
Careful use advised in patients with renal or hepatic impairment due to altered metabolism and clearance
Avoid use in individuals with a history of substance abuse or benzodiazepine dependence
Monitor for signs of drug addiction, misuse, or abuse with long-term or frequent dosing
Proper caregiver education essential for administration technique and seizure identification
Avoid sudden discontinuation to prevent acute withdrawal syndromes which can be life-threatening
Evaluate risk-benefit in elderly patients due to increased sensitivity and risk of sedation or falls
Avoid concomitant use with opioids or other CNS depressants unless closely supervised
Careful consideration needed for use during pregnancy and breastfeeding due to potential fetal/neonatal risks
Ensure clear differentiation between seizure types to ascertain appropriate use of Diastat AcuDial
Educate caregivers on seizure monitoring post-administration for timely emergency response
Address and manage potential leakage or bowel movements impacting drug delivery
Store medication properly and dispose of unused drug safely to prevent accidental ingestion
Precautionary use in patients with acute narrow angle glaucoma or known hypersensitivity to diazepam
Assess cognitive and motor function prior to activities requiring alertness following administration

Warnings

Potentially fatal respiratory depression and profound sedation may occur, especially with opioids
Federal law prohibits sharing or transferring this medication to others
Risk of serious side effects heightened in combination with alcohol or CNS depressants
Abrupt cessation may precipitate severe withdrawal symptoms including seizures and psychosis
Use contraindicated in infants under 6 months due to observed prolonged sedation
Serious respiratory events require immediate medical attention during or after use
Risk of misuse, abuse, and addiction necessitates careful patient selection and monitoring
Ensure caregivers receive comprehensive instruction to avoid dosing errors and complications
Should not be used in patients with acute narrow angle glaucoma
Risk of prolonged somnolence or sedation especially in elderly and debilitated patients
Potential for paradoxical reactions such as increased seizure frequency or aggressive behavior
Overdose may cause coma, respiratory arrest, or death necessitating urgent medical care
Use caution when used in combination with other medications metabolized by CYP3A4 or CYP2C19
Pregnancy risks, especially during first trimester, require consultation with healthcare provider
Monitor infants and children for excessive sedation following administration

Contraindication

Known hypersensitivity or allergy to diazepam or any component of the rectal gel formulation
Patients with acute narrow angle glaucoma
Concurrent use with opioids unless under strict medical supervision
Use in infants under 6 months due to risk of prolonged sedation and respiratory depression
Severe respiratory insufficiency where CNS depressant effects may exacerbate breathing difficulties
Myasthenia gravis due to muscle relaxant properties that may worsen muscle weakness
Severe liver impairment where metabolism and clearance of diazepam are compromised
Comatose states or severe CNS depression without airway protection
Sleep apnea syndrome because of increased risk of respiratory depression
Substance abuse or dependency history without adequate monitoring and control
Use in patients with acute intoxication with alcohol, hypnotics, narcotics, or other CNS depressants
Known hypersensitivity to any inactive ingredients such as benzyl alcohol or propylene glycol
Conditions where rectal administration is contraindicated, such as severe rectal inflammation
Concurrent administration with other benzodiazepines resulting in additive CNS depression
Patients unable to be properly monitored post-administration for respiratory or sedative side effects

Drug Interactions

Additive central nervous system depression with concomitant use of opioids leading to profound sedation, respiratory depression, or death
Enhanced sedative and respiratory depressive effects when combined with alcohol
Pharmacokinetic interactions with CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) increasing diazepam plasma levels
Reduced diazepam clearance with concomitant use of CYP2C19 inhibitors (e.g., omeprazole) leading to accumulation
Induction of diazepam metabolism by CYP3A4 inducers (e.g., carbamazepine, phenytoin) decreasing efficacy
Additive CNS depressant effects when used with other benzodiazepines, barbiturates, or sedative hypnotics
Potential increased risk of respiratory depression when used concurrently with muscle relaxants
Concomitant use with anticonvulsants like valproic acid may alter diazepam plasma concentrations
Interaction with cimetidine which can inhibit metabolism and prolong diazepam effects
Use with certain antidepressants (e.g., SSRIs) may potentiate sedation or alter metabolism
Enhanced effects when combined with antihistamines or antipsychotic agents with sedative properties
Interactions with theophylline or aminophylline may reduce benzodiazepine efficacy
Potential elevation of blood levels with macrolide antibiotics such as erythromycin due to CYP3A4 inhibition
Concurrent use with grapefruit juice may increase diazepam plasma concentration via CYP3A4 inhibition
Close monitoring required when combined with drugs affecting hepatic enzyme activity

Preparations Of The Drug

Diastat AcuDial rectal gel pre-filled syringes containing diazepam in concentrations of 2.5 mg, 5 mg, 10 mg, and 20 mg
Pre-filled plastic applicator with a flexible molded tip for rectal administration
Each syringe features a dose window and a green band indicating readiness for administration
Formulation includes inactive ingredients such as propylene glycol, alcohol, hypromellose, sodium benzoate, benzyl alcohol, benzoic acid, and water
Available in single-dose administration form designed for rapid rescue therapy for seizure clusters
Storage recommended at controlled room temperature (25°C or 77°F), with permitted excursions between 15°C to 30°C (59°F to 86°F)
Disposal instructions emphasize removal of plunger and flushing contents into the sink or toilet followed by discarding used materials in garbage
Authorized generic versions of diazepam rectal gel are available with similar composition
Supplied by Bausch Health US, manufactured by DPT Laboratories, Ltd, San Antonio, TX
Packaging designed to ensure dose accuracy and minimize dosing errors in emergency use
Lubricant jelly recommended for facilitating comfortable and effective rectal insertion
Not recommended for repeated or chronic administration outside of prescribed specifications due to addiction risk
Caregiver instruction materials provided with each product to ensure safe administration
Diastat 2.5 mg version available with a 4.4 cm tip, Diastat AcuDial 10 mg with 4.4 cm tip and 20 mg with 6.0 cm tip
Packaging includes tamper-evident seals and instructions for safe handling